Big news last week, as Merck's ISENTRESS (raltegravir & once known as MK-0518) 48 week phase 3 data came out:
"The 48-week results for ISENTRESS show that when paired with other anti-HIV medicines, ISENTRESS effectively lowered the amount of virus in the blood to undetectable levels in 62 percent of patients versus 33 percent of patients receiving placebo plus other anti-HIV medicines."
This is a much hyped blockbuster drug. Now compare this with avexa's atc:
"Avexa Reports Superior Results in ATC Phase IIb Clinical Trial Update 48 week data shows (over) 90% of treated patients achieve undetectable viral loads".
Unsure if I was comparing like with like, I rang avx this am, & spoke to Alan. He said that they had a meeting this morning & talked about the very same data & atc's superiority.
I said to him that as far as all the research I have done, atc appears to be the best HIV treatment in the world. He said that my findings are correct!
I asked him if atc should become a first line of therapy. He said it's easier for it to be released as a second line to start with, but then it's performance may well move it to a first line therapy.
Merck's full release via:
www.merck.com/newsroom/press_releases/product/2008_0723.html
- Forums
- ASX - By Stock
- worlds best hiv treatment
Big news last week, as Merck's ISENTRESS (raltegravir & once...
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online